October 1997

Combined Liver—Total Bowel Transplantation Has No Immunologic Advantage Over Total Bowel Transplantation AloneA Prospective Study in a Porcine Model

Author Affiliations

From the Departments of Surgery (Drs R. Gruessner, Benedetti, Pirenne, Troppmann, and A. Gruessner) and Anesthesiology (Drs Belani, Beebe, and Carr), University of Minnesota, Minneapolis, and the Department of Pathology (Dr Nakhleh), Henry Ford Hospital, Detroit, Mich.

Arch Surg. 1997;132(10):1077-1085. doi:10.1001/archsurg.1997.01430340031004

Background:  Rejection remains a major obstacle to successful bowel transplantation in humans. It has been suggested that a simultaneous liver transplant would shield the bowel graft from immunologic attack, but the liver shortage would be aggravated. In a preclinical model, we studied the influence of simultaneous liver grafting by comparing the incidence of early bowel rejection after combined liver—total (small- and large-) bowel transplants vs total bowel transplants alone.

Methods:  We assessed the incidence of early posttransplant rejection, graft-vs-host disease, and infection after combined liver—total bowel transplants (group 1, n=10) and total bowel transplants alone (group 2, n=9) in outbred Yorkshire Landrace pigs. Liver and bowel grafts were transplanted orthotopically with portal vein drainage after recipient hepatectomy (group 1) and total enterectomy (groups 1 and 2). Posttransplant immunosuppression was performed with intravenous tacrolimus (whole blood levels, 15 to 30 ng/mL) and prednisolone. In groups 1 and 2, bowel biopsy specimens from the ileostomy were obtained daily. In group 1, liver biopsy specimens were obtained weekly. Rejection was graded according to a 4-point scoring system (none, mild, moderate, and severe).

Results:  Overall graft survival at days 7, 14, and 21 was 89%, 44%, and 11%, respectively, in group 1 vs 100%, 100%, and 86%, respectively, in group 2 (P<.001). Death rates owing to (irreversible) rejection at days 7, 14, and 21 were 0% in groups 1 and 2 (P=.48). Grading of bowel rejection episodes, based on the results of daily biopsy specimans, was not significantly different between the groups whether on individual days or overall. In group 1, the incidence of liver rejection episodes was as high as 66% (day 14 and at autopsy). At autopsy, generalized graft-vs-host disease (skin, native intestine, and native liver) was noted in 55% of group 1 and 43% of group 2 pigs (P=.55). Graft-vs-host disease was noted concurrently with rejection episodes of the liver or bowel grafts.

Conclusions:  Simultaneous liver grafting did not further reduce the incidence of early bowel rejection or graft-vs-host disease when compared with total bowel transplants alone. Based on the results of this preclinical study, simultaneous liver grafting is not indicated for patients with short-bowel syndrome and normal liver function.Arch Surg. 1997;132:1077-1085